Literature DB >> 22302471

Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy.

Hirotaka Takasaki1, Masatsugu Tanaka, Takayoshi Tachibana, Ayumi Numata, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Naoto Tomita, Hiroyuki Fujita, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori.   

Abstract

We retrospectively analyzed patients aged C 50 years with hematologic malignancies who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) to identify preoperative variables predicting the outcome. There were 71 patients with a median age of 57 years (range: 50-63 years) who had acute leukemia (n = 53) or myelodysplastic syndrome (n = 18). Myeloablative conditioning was done in 35 patients and 36 patients had reduced-intensity conditioning. The 5-year overall survival rate (OS), cumulative relapse rate, and non-relapse mortality rate (NRM) were 45, 24, and 33%, respectively. According to multivariate analysis, high-risk disease (HR 3.50, 95% CI 1.43-8.56, P = 0.006), a hematopoietic cell transplantation comorbidity index (HCT-CI) score ≥ 3 (HR 4.41, 95% CI 1.31-14.77, P = 0.016), and an HLA-mismatched unrelated donor (HR 4.03, 95% CI 1.46-11.10, P = 0.007) were significant predictors of worse OS. Highrisk disease was also significantly associated with a higher cumulative relapse rate (HR 4.59, 95% CI 0.94-6.92, P = 0.065). Furthermore, an HCT-CI score ≥ 3 (HR 3.02, 95% CI 1.01-20.78, P = 0.048) and an HLA-mismatched unrelated donor (HR 3.02, 95% CI 1.04-8.74, P = 0.042) were risk factors for NRM. These results suggest that the disease risk, HCT-CI score, and donor type/histocompatibility are prognostic factors for elderly patients, while the conditioning regimen and age are not predictors.

Entities:  

Mesh:

Year:  2012        PMID: 22302471     DOI: 10.1007/s12185-012-1009-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.

Authors:  Andrew S Artz; Daniel A Pollyea; Masha Kocherginsky; Wendy Stock; Elizabeth Rich; Olatoyosi Odenike; Todd Zimmerman; Sonali Smith; Lucy Godley; Michael Thirman; Christopher Daugherty; Martine Extermann; Richard Larson; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2006-09       Impact factor: 5.742

2.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

Authors:  Mohamed L Sorror; Sergio Giralt; Brenda M Sandmaier; Marcos De Lima; Munir Shahjahan; David G Maloney; H Joachim Deeg; Frederick R Appelbaum; Barry Storer; Rainer Storb
Journal:  Blood       Date:  2007-09-14       Impact factor: 22.113

3.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

4.  Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.

Authors:  S W Bokhari; L Watson; S Nagra; M Cook; J L Byrne; C Craddock; N H Russell
Journal:  Bone Marrow Transplant       Date:  2011-07-11       Impact factor: 5.483

5.  Prognostic factors in allo-SCT of elderly patients with AML.

Authors:  J Krauter; K Wagner; M Stadler; E Dammann; M Zucknick; M Eder; S Buchholz; E Mischak-Weissinger; B Hertenstein; A Ganser
Journal:  Bone Marrow Transplant       Date:  2010-06-14       Impact factor: 5.483

6.  Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000).

Authors:  Yoshinobu Kanda; Shigeru Chiba; Hisamaru Hirai; Hisashi Sakamaki; Tohru Iseki; Yoshihisa Kodera; Takahiro Karasuno; Shinichiro Okamoto; Noriyuki Hirabayashi; Koji Iwato; Atsuo Maruta; Yoshihiro Fujimori; Tatsuo Furukawa; Shin Mineishi; Keitaro Matsuo; Nobuyuki Hamajima; Masahiro Imamura
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

7.  A risk score for mortality after allogeneic hematopoietic cell transplantation.

Authors:  Tanyalak Parimon; David H Au; Paul J Martin; Jason W Chien
Journal:  Ann Intern Med       Date:  2006-03-21       Impact factor: 25.391

8.  Allogeneic myeloablative transplantation for patients aged 50 years and over.

Authors:  M Yanada; N Emi; T Naoe; H Sakamaki; T Iseki; N Hirabayashi; T Karasuno; S Chiba; Y Atsuta; N Hamajima; S Takahashi; S Kato
Journal:  Bone Marrow Transplant       Date:  2004-07       Impact factor: 5.483

9.  Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients aged 50 years and over.

Authors:  Katsumichi Fujimaki; Masatsugu Tanaka; Hirotaka Takasaki; Rie Hyo; Tomoko Kawano; Rika Sakai; Hiroyuki Fujita; Shin Fujisawa; Heiwa Kanamori; Atsuo Maruta; Yoshiaki Ishigatsubo
Journal:  Intern Med       Date:  2008-03-03       Impact factor: 1.271

10.  The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

Authors:  L Farina; B Bruno; F Patriarca; F Spina; R Sorasio; M Morelli; R Fanin; M Boccadoro; P Corradini
Journal:  Leukemia       Date:  2009-02-05       Impact factor: 11.528

View more
  5 in total

1.  Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.

Authors:  Tanya M Wildes; Derek L Stirewalt; Bruno Medeiros; Arti Hurria
Journal:  J Natl Compr Canc Netw       Date:  2014-01       Impact factor: 11.908

2.  IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Authors:  Yoshitaka Zaimoku; Akiyoshi Takami; Hidehiro Sato; Maki Utsumi; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-05-10       Impact factor: 2.490

Review 3.  Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.

Authors:  S Fadilah Abdul Wahid; Nor-Azimah Ismail; Mohd-Razif Mohd-Idris; Fariza Wan Jamaluddin; NorRafeah Tumian; Ernie Yap Sze-Wei; Norasiah Muhammad; Ming Lai Nai
Journal:  Stem Cells Dev       Date:  2014-09-17       Impact factor: 3.272

Review 4.  Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns.

Authors:  Zeina Al-Mansour; Muthalagu Ramanathan; Jan Cerny
Journal:  Drugs Aging       Date:  2018-12       Impact factor: 3.923

5.  To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision.

Authors:  Aaron T Gerds; Frederick R Appelbaum
Journal:  Clin Adv Hematol Oncol       Date:  2012-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.